KERYX BIOPHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Cash flows from operating activities
Net loss
Loss from continuing operations
Adjustments to reconcile loss to cash flows used in operating activities:
Stock-based compensation expense
Amortization of debt discount
Change in fair value of derivative liability
Depreciation and amortization
Loss on disposal of fixed assets
Write-down of inventory to net realizable value
Cash received from landlord
Amortization of deferred lease incentive
Deferred income taxes
Changes in operating assets and liabilities:
Other current assets
Accounts receivable, net
Accrued interest receivable
Inventory
Other current liabilities
Security deposits
Other assets
Accounts payable and accrued expenses
Accrued compensation and related liabilities
Deferred revenue
Other liabilities
Net cash used in operating activities

Cash flows from investing activities
Purchases of property, plant and equipment
Investment in held-to-maturity short-term securities
Proceeds from maturity of held-to-maturity short-term securities
Net cash (used in) provided by investing activities
Net cash (used in) provided by investing activities
Gross proceeds from public offerings
Proceeds from issuance of common stock, net of commission
Payments for common stock issuance costs
Proceeds from exercise of options
Payments for repurchase of common stock for employee tax withholding
Net cash provided by financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Non-cash investing and financing activities
Reclassification of derivative liability to equity
Increase of receivable from landlord and deferred lease incentive

Comments